Reducing Treatment Burden and Health Disparities via On-Body Injectors

Sikander Ailawadhi, MD, of the Mayo Clinic Florida in Jacksonville, highlights the transformative potential of a subcutaneous (SC) formulation of isatuximab (Sarclisa), particularly when delivered via an on-body injector (OBI). While the clinical efficacy of monoclonal antibodies has revolutionized multiple myeloma care, the logistical requirements of intravenous (IV) administration remain a significant hurdle. Ailawadhi argues that transitioning to an OBI-based system offers a “global benefit” that extends far beyond clinical outcomes, addressing the practical, financial, and social burdens of cancer treatment.

Alleviating Time and Financial Toxicity

Traditional IV infusions necessitate frequent and lengthy visits to specialized centers, which impacts both patients and their families. The benefits of home-based or simplified administration include reduced patient burden, eliminating the need for significant time away from work and family responsibilities. Many patients require a caregiver for transportation and support; a self-administered option reduces the strain on these support networks. By reducing the number of lost workdays and travel expenses, the OBI can help alleviate some of the financial toxicity associated with chronic cancer care.

Bridging the Gap in Healthcare Disparities

A major concern in the U.S. healthcare system is the disparity in access for patients living in rural or “far-flung” areas. Many patients reside hours away from the nearest infusion center, making frequent back-and-forth travel nearly impossible.

The OBI serves as a critical tool for health equity. If patients can have the drug delivered to their homes or collect it during a less frequent visit, they can self-administer the treatment by simply applying the device. This accessibility ensures that monoclonal antibodies, which are considered “game changers” in myeloma, reach a wider and more diverse patient population, regardless of their proximity to a major medical institution or their ability to afford frequent travel.

The Future of Self-Administered Oncology

Ultimately, the goal is to shift oncology toward a more patient-centric model. By simplifying the delivery of complex biologics like isatuximab, the myeloma community can ensure that high-quality care is determined by medical need rather than a patient's geographic location or socioeconomic status. This shift promises to improve quality of life while maintaining the high efficacy standards required for treating relapsed or refractory multiple myeloma.